Getty Images
February 23, 2023 — Lexicon Pharmaceuticals, Inc. announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana.
The following analyses of sotagliflozin have been selected for presentation:
- “Time to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF”, a moderated poster presentation on Saturday, March 4th at 11:00 am CT
- “Effects of SGLT 1-2 Inhibitor Sotagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients with Worsening Heart Failure: Results from the SOLOIST Trial”, a moderated poster presentation on Saturday, March 4th at 10:15 am CT
- “Levels of Soluble Urokinase Plasminogen Activator Receptor and Heart Failure Outcomes in Patients with Type 2 Diabetes and Worsening Heart Failure Treated with Sotagliflozin, a Dual SGLT 1 and SGLT 2 Inhibitor”, a poster presentation on Sunday, March 5th at 2:45 pm CT
- “Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Modulated Expression of Atheroprotective Proteins during Inflammation Compared with Empagliflozin”, a moderated poster presentation on Monday, March 6th at 10:30 am CT
About the SOLOIST-WHF Study
SOLOIST-WHF was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.
SOLOIST-WHF achieved its primary endpoint, with overall tolerability similar to placebo. Results were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in an article titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” which may be accessed at www.nejm.org.
March 25, 2026 
